Mitsubishi Chemical Group (4188) Q4 2025 earnings summary

Executive summary

• FY2024 saw stable business conditions, with strong display and semiconductor-related sales, but sluggish demand in automotive and food sectors.

• Core operating income rose 43% year-over-year to ¥298.4 billion, driven by improved price gaps and higher sales volumes, especially in chemicals.

• Net income attributable to owners fell 62% year-over-year to ¥45.0 billion due to structural reform expenses.

• Major structural reforms and portfolio transformation initiatives are underway, including the planned transfer of the Pharma business and capacity expansions in specialty and industrial segments.

• FY2025 core operating income is forecast at ¥265 billion, with net income projected at ¥145 billion, reflecting proceeds from the Mitsubishi Tanabe Pharma transfer.

Financial highlights

• Sales revenue for FY2024 was ¥4,407.4 billion, nearly flat year-over-year.

• Core operating income increased to ¥298.4 billion from ¥208.1 billion, a 43% rise year-over-year.

• Net income attributable to owners dropped to ¥45.0 billion, down 62% year-over-year, mainly due to special losses.

• Free cash flow improved to ¥277.4 billion from ¥219.1 billion year-over-year; operating cash flow was ¥552.8 billion.

• Net debt-to-equity ratio improved to 1.06 from 1.16 year-over-year.

Outlook and guidance

• FY2025 sales revenue is forecast at ¥3,740.0 billion, down 5% due to the Pharma business transfer.

• Core operating income is expected to rise 16% to ¥265.0 billion; chemicals business core operating income to increase 78% to ¥76.0 billion.

• Net income attributable to owners is projected at ¥145.0 billion, up 222% year-over-year, mainly from the Pharma divestiture.

• Annual dividend forecast for FY2025 is ¥32 per share, unchanged from FY2024; ¥50 billion share buyback planned.

• Profit from discontinued operations (Mitsubishi Tanabe Pharma) expected at ¥94 billion, included in Q1.